News

FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
PharmExec2d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
Stocktwits on MSN2d
Moderna’s RSV Vaccine Gets FDA Nod For Younger At-Risk Adults: Retail Stays Guarded Amid RFK Jr’s Immunization Shake-Up
Moderna, Inc. (MRNA) announced late Thursday that the U.S. Food and Drug Administration (FDA) has approved its respiratory ...
Pharmaceutical Technology on MSN2d
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults
The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.
STAT3d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
BioPharma Dive2d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Seeking Alpha3d
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's ...